60
Participants
Start Date
February 16, 2023
Primary Completion Date
April 12, 2024
Study Completion Date
April 18, 2024
Daridorexant
Daridorexant is available as oral film-coated tablets at a strength of 50 mg.
Placebo
Placebo matching daridorexant is provided as identical-looking oral tablets, formulated with the same inactive ingredients (excipients) as the active tablets.
ASR Advanced Sleep Research GmBH, Berlin
Hospital Universitario Puerta del Mar (HUPM), Cadiz
Complejo Hospitalario Universitario A Coruña, A Coruña
SOMNIBENE Institut für Medizinische Forschung und Schlafmedizin Schwerin GmbH, Schwerin
Accellacare Research of Cary, Cary
Hospital Universitario Fundación Jiménez Díaz, Madrid
Hospital Universitario La Paz, Madrid
Hospital Universitario Central de Asturias, Oviedo
Clinical Research Center of Florida, Pompano Beach
Quantum Clinical Trials, Miami Beach
Encore Medical Research of Weston, Weston
Hospitalario Universitario de Canarias, San Cristóbal de La Laguna
Praxisklinik am Franziskushospital - Urologisches Zentrum Euregio, Aachen
Ochsner LSU Health Shreveport-Regional Urology, Shreveport
Hospital del Mar, Barcelona
UROCLINICA Barcelona, Barcelona
Lead Sponsor
Idorsia Pharmaceuticals Ltd.
INDUSTRY